Teva Pharmaceuticals and Syqe Medical say the device is the first in the medical cannabis sector that complies with pharmaceutical standards for inhalation.
Teva shares hammered a second day after disappointing third quarter | After two tough quarters, Delta-Galil profit climbs 31% | Tel Aviv has another quiet day as Wall Street opens lower
Bloomberg News report says first charges in wide-ranging investigation could come next month. News of the investigation comes at a sensitive time for the global drug industry, which has been stung by repeated charges of price gouging.
Mylan shares jump on EpiPen agreement; bond offerings surge; Kenon suffers in the second quarter; stocks inch up.
Platform will monitor and analyze key symptoms of neurodegenerative disease that impact daily living.
EpiPen's list price has soared from less than $100 when Mylan acquired the product in 2007, to more than $600 now, sparking outrage. Without strong competitors, Mylan's EpiPen still holds an estimated 94 percent market share.
Amid win against Teva, Mylan caves in to pressure and offers EpiPen discount | Ethiopia says Israel Chemicals owes $55 million in taxes on potash project | Pharma woes weigh on Tel Aviv shares
Drug maker beats analysts’ estimates for earnings and revenues as Copxone sales rise.
Anda, the fourth-largest U.S. distributor of generic pharmaceuticals, is on track to earn $1.5 billion in third-party net revenue and 15 cents in earnings per share.
Federal Trade Commission clears deal after Israeli drug maker agrees to sell 79 generic drugs to rival firms.